Pill Identifier App

Treprostinil Pregnancy and Breastfeeding Warnings

Treprostinil is also known as: Orenitram, Remodulin, Tyvaso

Treprostinil Pregnancy Warnings

Oral formulation: FDA pregnancy category C Infusion or inhalation: FDA pregnancy category B Potential benefit should outweigh the potential risk.

Oral formulation: Animal reproductive studies have shown an adverse effect on the fetus. Infusion or inhalation: Studies in rats have failed to reveal evidence of fetotoxicity or teratogenicity. An increased incidence of fetal skeletal variations associated with maternal toxicity were reported in rabbit studies (at 41 times the human starting dose). There are no controlled data in human pregnancy. FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women. FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Treprostinil Breastfeeding Warnings

Oral formulation: A decision should be made to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother. Infusion or inhalation: Caution is recommended. Excreted into human milk: Unknown The effects in the nursing infant are unknown.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web5)